Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotype-guided P2Y12 inhibitor monotherapy versus individualized dual antiplatelet therapy after elective PCI
NL-OMON52565Phase 4Withdrawn
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Oct 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, ticagrelor, prasugrel and aspirin in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (3 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Planned start Oct 2020; status: withdrawn.
02
Drugs
clopidogrelticagrelorprasugrelaspirin
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON52565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52565.